P53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes

Modern Pathology

Volumn 23, Issue 1, 2010, Pages 80-92

  Garg, Karuna ^a   Leitao, Mario M ^a   Wynveen, Christine A ^a   Sica, Gabriel L ^a   Shia, Jinru ^a   Shi, Weiji ^a   Soslow, Robert A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Endometrial carcinoma; Outcome; P53

Indexed keywords

PROTEIN P53;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OBSERVER VARIATION; PATHOLOGIST; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR CLASSIFICATION;

ADULT; AGED; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; OBSERVER VARIATION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73949154691     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.153     Document Type: Article

References (56)

1. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adeno-carcinomas: a clinicopathologic and immunohisto-chemical study of a group of problematic cases. Am J Surg Pathol 2004;28:1568-1578.
2. Lomo L, Nucci MR, Lee KR, et al. Histologic and immunohistochemical decision making in endometrial adenocarcinoma. Mod Pathol 2008;21:937-942.
3. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17.
4. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study of 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992;47:298-305.
5. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13: 295-308.
6. Hendrickson M, Ross J, Eifel P, et al. Uterine papillary serous carcinoma: a highly malignant form of endo-metrial adenocarcinoma. Am J Surg Pathol 1982;6: 93-108.
7. Murray SK, Young RH, Scully RE. Uterine endome-trioid carcinoma with small nonvillous papillae: an analysis of 26 cases of a favorable prognosis tumor to be distinguished from serous carcinoma. Int J Surg Pathol 2000;8:279-289.
8. Parkash V, Carcangiu ML. Endometrioid endometrial adenocarcinoma with psammoma bodies. Am J Surg Pathol 1997;21:399-406. (Pubitemid 27184772)
9. Bristow RE, Asrari F, Trimble EL, et al. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (stage I-III) disease. Gyn Oncol 2001;81:279-286.
10. Tay EH, Ward BG. The treatment of uterine papillary serous carcinoma (UPSC): are we doing the right thing? Int J Gynecol Cancer 1999;9:463-469.
11. Lee KR, Belinson JL. Recurrence in noninvasive endometrial carcinoma: relationship to uterine papillary serous carcinoma. Am J Surg Pathol 1991;15: 965-973.
12. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992;16:600-610.
13. Soslow RA, Bissonnette JP, Wilton A, et al. Clinico-pathologic analysis of 187 high grade endometrial carcinomas of different histologic subtypes: similar outcome belies distinctive biologic differences. Am J Surg Pathol 2007;31:979-987.
14. Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003;91:463-469.
15. Carcangiu ML, Tan LK, Chambers JT. Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 1997;21:1507-1514.
16. Geisler JP, Geisler HE, Wiemann MC, et al. p53 expression as a prognostic indicator of 5 year survival in endometrial cancer. Gynecol Oncol 1999;74: 468-471.
17. Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54:264-268.
18. Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991;6:1699-1703.
19. Chang K, Ding I, Kern FG, et al. Immunohistochemical analysis of p53 and her-2/neu proteins in human tumors. J Histochem Cytochem 1991;39:1281-1287.
20. Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-679.
21. Soong R, Robbins PD, Dix BR, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 1996;27:1050-1055.
22. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993;329: 1318-1327.
23. Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004;23:129-137.
24. Moll UM, Chalas E, Auguste M, et al. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol 1996;27:1295-1300.
25. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and ki-67, p53 and p21 expression: a population based endometrial carcinoma study. J Clin Oncol 1999;17:1382-1390.
26. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-185.
27. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, k-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma, evidence of distinct molecular genetic pathways. Cancer 2000;88:814-824.
28. Bur ME, Perlman C, Edelmann L, et al. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98:81-87.
29. King SA, Adas AA, Livolsi VA, et al. Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer 1995;75:2700-2705.
30. Sherman ME, Bur ME, Kurman RJ. P53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995; 26:1268-1274.
31. Egan JA, Ionescu MC, Eapen E, et al. Differential expression of WT1 and p53 in serous and endome-trioid carcinomas of the endometrium. Int J Gynecol Pathol 2004;23:119-122.
32. Halperin R, Zehavi S, Habler L, et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001;22:122-126. (Pubitemid 32963063)
33. Soslow RA, Shen PU, Chung MH, Isacson C. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 1998;17:129-134.
34. Hamel NW, Sebo TJ, Wilson TO, et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 1996;62:192-198.
35. Pisani AL, Barbuto DA, Chen D, et al. Her-2/neu, p53 and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995;85: 729-734.
36. Powell B, Soong R, Grieu F, et al. p53 protein overexpression is a prognostic indicator of poor survival in stage 1 endometrial carcinoma. Int J Oncol 1999;14:175-179.
37. Silverman MB, Roche PC, Kho RM. Molecular and cytokinetic pretreatment risk assessment in endome-trial carcinoma. Gyn Oncol 2000;77:1-7.
38. Athanassiadou P, Athanassiades P, Grapsa D, et al. The prognostic value of PTEN, p53 and beta-catenin in endometrial carcinoma: a prospective immunocyto-chemical study. Int J Gynecol Cancer 2007;17:697-704.
39. Lukes AS, Kohler MF, Pieper CF, et al. Multivariable analysis of DNA ploidy, p53 and her-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-2385.
40. Remmele W, Stegner HE. Recommendations for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987;8: 138-140.
41. Faratian D, Stillie A, Busby-Earle RMC, et al. A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int J Gynecol Cancer 2006;16:972-978.
42. Zaino RJ, Kurman RJ, Diana KL, et al. The utility of revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocar-cinoma using a defined nuclear grading system. Cancer 1995;75:81-86.
43. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high grade serous carcinoma. Int J Gynecol Pathol 2007;26: 328-333.
44. O'Neill CJ, McCluggage WG. P16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006;13:8-15.
45. Reid-Nicholson M, Iyengar P, Hummer AJ, et al. Immunophenotypic diversity of endometrial adeno-carcinomas: implications for differential diagnosis. Mod Pathol 2006;19:1091-1100.
46. Engelson IB, Stefansson I, Akslen LA. Pathologic expression of p53 or p16 in preoperative curettage specimens identified high risk endometrial carcinomas. Am J Obst Gynecol 2006;195:979-986.
47. Alkushi A, Clarke BA, Akbari M, et al. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007;20: 1156-1165.
48. Risinger JL, Hayes K, Maxwell GL. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005-3010.
49. Pallares J, Bussaglia E, Martinez-Guitarte JL, et al. Immunohistochemical analysis of PTEN in endome-trial carcinomas: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005;18:7159-7727.
50. Alkushi A, Kobel M, Kalloger SE, et al. High grade endometrial carcinoma: serous and grade 3 endome-trioid carcinoma have different immunophenotypes and outcomes. Modern Path 2009;22:206A.
51. Geisler JP, Geisler HE, Miller GA, et al. MIB-1 in endometrial carcinoma: prognostic significance with 5-year follow-up. Gynecol Oncol 1999;75:432-436.
52. Kallakury BV, Ambros RA, Hayner-Buchan AM, et al. Cell proliferation associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes. Int J Gynecol Pathol 1998;17: 320-326.
53. Salvesen HB, Iverson OE, Akslen LA. Identification of high risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 1998;4:2779-2785.
54. Alkushi A, Lim P, Aquino-Parsons C, et al. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 2002;15:365-371.
55. Jarboe EA, Pizer ES, Miron A, et al. Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol 2009;22:345-350 doi: 10.1038.
56. Jia L, Liu Y, X Y, et al. Endometrial glandular dysplasia with frequent p53 mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 2008;14:2263-2269.